A Substudy to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants
A Phase 1, Open-Label, Single Dose, Fixed-Sequence Crossover Sub Study to Determine the Pharmacokinetics Using Tasso Device and Safety and Tolerability Using Wearable Monitoring Devices Following Single Oral Doses of Etrasimod 2 mg IR Tablets in Healthy Adult Participants in a Hybrid Decentralized Clinical Trial Design
Category & Conditions: Immune System Diseases and Conditions
Medicine: ETRASIMOD
ClinicalTrials.gov Identifier (NCT): NCT06140290
Protocol ID: C5041050
Open Plain Language Summary Result:
Click here